A Phase 3 interventional study of SHR-1918/ SHR-1918 placebo and SHR-1918/ SHR-1918 placebo in Hypertriglyceridemia, sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment
The purpose of the study is to evaluate the efficacy and safety of SHR-1918 in patients with hypertriglyceridemia. The efficacy and safety of SHR-1918 will be evaluated after 24-weeks and 48-weeks treatment.
324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.
This study's enrollment of 367 is above the median of 66 across 288 interventional studies indexed under Hypertriglyceridemia.
Browse Hypertriglyceridemia studies →Beijing Suncadia Pharmaceuticals Co., Ltd is the lead sponsor of 25 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SHR-1918/ SHR-1918 placebo
Drug: SHR-1918/ SHR-1918 placebo
SHR-1918/ SHR-1918 placebo Dose 1
SHR-1918/ SHR-1918 placebo Dose 2
Percentage change in mean serum triglyceride (TG) levels at Week 20 and Week 24 relative to baseline
Time frame: at 20 weeks and 24 weeks of treatment
Percentage change in non-HDL-C relative to baseline
Time frame: at 24 weeks of treatment
Percentage change in LDL-C relative to baseline
Time frame: at 24 weeks of treatment
Percentage change in TC relative to baseline
Time frame: at 24 weeks of treatment
Percentage change in ApoB relative to baseline
Time frame: at 24 weeks of treatment
Percentage change in ApoA1 relative to baseline
Time frame: at 24 weeks of treatment
Change in TG relative to baseline
Time frame: at 24 weeks of treatment
Change in non-HDL-C relative to baseline
Time frame: at 24 weeks of treatment
Change in LDL-C relative to baseline
Time frame: at 24 weeks of treatment
Change in TC relative to baseline
Time frame: at 24 weeks of treatment
Change in ApoB relative to baseline
Time frame: at 24 weeks of treatment
Change in ApoA1 relative to baseline
Time frame: at 24 weeks of treatment
Change and percentage change in Lp(a) relative to baseline
Time frame: at 24 weeks of treatment
Change and percentage change in HDL-C relative to baseline
Time frame: at 24 weeks of treatment
Proportion of subjects with TG < 1.7 mmol/L
Time frame: at 24 weeks and 48 weeks of treatment
Change and percentage change in non-HDL-C relative to baseline
Time frame: at 48 weeks of treatment
Change and percentage change in LDL-C relative to baseline
Time frame: at 48 weeks of treatment
Change and percentage change in TC relative to baseline
Time frame: at 48 weeks of treatment
Change and percentage change in ApoB relative to baseline
Time frame: at 48 weeks of treatment
Change and percentage change in ApoA1 relative to baseline
Time frame: at 48 weeks of treatment
Change and percentage change in Lp(a) relative to baseline
Time frame: at 48 weeks of treatment
Change and percentage change in HDL-C relative to baseline
Time frame: at 48 weeks of treatment
Change and percentage change in TG relative to baseline
Time frame: at 48 weeks of treatment
Proportion of subjects who received rescue treatment
Time frame: Approximately a year
Incidence and severity of adverse events and injection site reactions
Time frame: Approximately a year
Plan to share: Undecided
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Suncadia Pharmaceuticals Co., Ltd →